Quote | Oncolytics Biotech Inc. (TSXC:ONC:CC)
Last: | $1.52 |
---|---|
Change Percent: | -1.94% |
Open: | $1.55 |
Close: | $1.55 |
High: | $1.55 |
Low: | $1.48 |
Volume: | 36,421 |
Last Trade Date Time: | 12/31/1969 07:00:00 pm |
News | Oncolytics Biotech Inc. (TSXC:ONC:CC)
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights PR Newswire Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- met...
2024-05-09 12:15:23 ET Palm Beach, FL – May 9, 2024 – FN Media Group News Commentary – The incidence of pancreatic cancer is increasing globally, which is driving the growth of the market. As of 2023, the American Cancer Society predicts that 64,050 American...
Message Board Posts | Oncolytics Biotech Inc. (TSXC:ONC:CC)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Oncolytics Biotech Inc. Company Name:
ONC:CC Stock Symbol:
TSXC Market:
Oncolytics Biotech® Reports First Quarter 2024 Financial Results and Operational Highlights PR Newswire Pelareorep advancing to registration-enabling studies Preparations underway for Type C meeting with the FDA to establish registrational pathway in HR+/HER2- met...
Gold Springs Resource Corp. (GRC:CA) is expected to report for Q1 2024 Primo Water Corporation (PRMW:CA) is expected to report $0.18 for Q1 2024 Greenlane Renewables Inc. (GRN:CA) is expected to report $-0.01 for Q1 2024 Kelso Technologies Inc. (KLS:CA) is expected to report for Q1 20...
Oncolytics Biotech® Receives Regulatory Clearance to Evaluate Pelareorep in Combination with Modified FOLFIRINOX +/- an anti-PD-L1 Inhibitor in Pancreatic Cancer PR Newswire US$5 million PanCAN grant provides important support for the fifth cohort of the GOBLET study ...